Literature DB >> 17493004

A curcumin-based 1-week triple therapy for eradication of Helicobacter pylori infection: something to learn from failure?

Francesco Di Mario1, Lucas G Cavallaro, Antonio Nouvenne, Nicoletta Stefani, Giulia M Cavestro, Veronica Iori, Marta Maino, Giuseppe Comparato, Libera Fanigliulo, Ester Morana, Alberto Pilotto, Laura Martelli, Mario Martelli, Gioacchino Leandro, Angelo Franzè.   

Abstract

BACKGROUND: Curcumin is the principal element of turmeric powder extracted from the root of Curcuma longa. Studies on curcumin have demonstrated some anti-Helicobacter pylori activity as well as immunomodulating properties. N-acetylcysteine and lactoferrin with their respective mucolytic and antibacterial activities might also be effective in H. pylori eradication therapy. AIM: To determine if a 7-day non-antibiotic therapy comprised of curcumin, lactoferrin, N-acetylcysteine, and pantoprazole was effective for eradication of H. pylori infection and reduction of gastric inflammation, assessed by serum pepsinogens and relief of symptoms. SUBJECTS AND METHODS: Twenty-five consecutive H. pylori-positive patients (12 males, mean age 50 +/- 12 years, range 31-76) with functional dyspepsia were enrolled. Patients were administered for 7 days curcumin 30 mg b.i.d., bovine lactoferrin 100 mg b.i.d., N-acetylcysteine 600 mg b.i.d., and pantoprazole 20 mg b.i.d. H. pylori status and upper gastrointestinal symptoms were assessed by (13)C-urea breath test and a scale of upper gastrointestinal symptoms intensity (absent, mild, moderate, and severe), as well as a blood test for serum pepsinogens (sPGI, sPGII), gastrin-17 (G-17), and anti-H. pylori IgG (IgG-Hp) at baseline (T0) and after 2 months (T1).
RESULTS: Three of 25 patients (12%) were cured of H. pylori infection. A significant decrease in the overall severity of symptoms (T0: 6, interquartile range [IQR]: 4.5-8; T1: 2, IQR: 2-3; p < or = .001), and sPGII (T0: 16 microg/L, IQR: 13-22; T1: 10 microg/L, IQR: 8-16; p < or = .001) and sPGI (T0: 82 microg/L, IQR: 67-97; T1: 74 microg/L, IQR: 62-94; p = .02) levels were observed after 2 months of the treatment. IgG and G-17 values did not significantly decrease after 2 months.
CONCLUSIONS: This novel therapy was not effective for H. pylori eradication. However, despite the bacterium persistence, significant improvement of dyspeptic symptoms and reduction of serologic signs of gastric inflammation were observed after 2 months at the end of the 7-day treatment schedule.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17493004     DOI: 10.1111/j.1523-5378.2007.00497.x

Source DB:  PubMed          Journal:  Helicobacter        ISSN: 1083-4389            Impact factor:   5.753


  27 in total

1.  Epigenetic changes induced by curcumin and other natural compounds.

Authors:  Simone Reuter; Subash C Gupta; Byoungduck Park; Ajay Goel; Bharat B Aggarwal
Journal:  Genes Nutr       Date:  2011-04-24       Impact factor: 5.523

Review 2.  Antibiotic resistance breakers: can repurposed drugs fill the antibiotic discovery void?

Authors:  David Brown
Journal:  Nat Rev Drug Discov       Date:  2015-10-23       Impact factor: 84.694

Review 3.  Curcumin, the golden nutraceutical: multitargeting for multiple chronic diseases.

Authors:  Ajaikumar B Kunnumakkara; Devivasha Bordoloi; Ganesan Padmavathi; Javadi Monisha; Nand Kishor Roy; Sahdeo Prasad; Bharat B Aggarwal
Journal:  Br J Pharmacol       Date:  2016-10-21       Impact factor: 8.739

Review 4.  Therapeutic roles of curcumin: lessons learned from clinical trials.

Authors:  Subash C Gupta; Sridevi Patchva; Bharat B Aggarwal
Journal:  AAPS J       Date:  2012-11-10       Impact factor: 4.009

5.  Symptom-based tendencies of Helicobacter pylori eradication in patients with functional dyspepsia.

Authors:  Ling Lan; Jing Yu; Yu-Long Chen; Ya-Li Zhong; Hao Zhang; Chang-He Jia; Yuan Yuan; Bo-Wei Liu
Journal:  World J Gastroenterol       Date:  2011-07-21       Impact factor: 5.742

Review 6.  Effects of Curcumin and Its Analogues on Infectious Diseases.

Authors:  Reza Ranjbar; Hossein Bagheri; Faezeh Ghasemi; Paul C Guest; Amirhossein Sahebkar
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

Review 7.  Curcumin: an orally bioavailable blocker of TNF and other pro-inflammatory biomarkers.

Authors:  Bharat B Aggarwal; Subash C Gupta; Bokyung Sung
Journal:  Br J Pharmacol       Date:  2013-08       Impact factor: 8.739

Review 8.  Chili Peppers, Curcumins, and Prebiotics in Gastrointestinal Health and Disease.

Authors:  Tanisa Patcharatrakul; Sutep Gonlachanvit
Journal:  Curr Gastroenterol Rep       Date:  2016-04

Review 9.  Curcumin as a potential therapeutic candidate for Helicobacter pylori associated diseases.

Authors:  Avijit Sarkar; Ronita De; Asish K Mukhopadhyay
Journal:  World J Gastroenterol       Date:  2016-03-07       Impact factor: 5.742

Review 10.  Helicobacter pylori associated Asian enigma: Does diet deserve distinction?

Authors:  Syed Faisal Zaidi
Journal:  World J Gastrointest Oncol       Date:  2016-04-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.